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Purpose: To analyze the feasibility of omitting clinical target volume (CTV) for limited small cell lung cancer treated
with chemotherapy and intensity modulated radiotherapy.
Methods and materials: 89 patients were treated from January 1, 2008 to August 31, 2011, 54 cases were irradiated
with target volume without CTV, and 35 cases were irradiated with CTV. Both arms were irradiated post chemotherapy
tumor extent and omitted elective nodal irradiation; dose prescription was 95% PTV56-63 Gy/28-35 F/5.6-7 weeks.
Results: In the arm without CTV and arm with CTV, the local relapse rates were 16.7% and 17.1% (p = 0.586) respectively.
In the arm without CTV, of the 9 patients with local relapse, 6 recurred in-field, 2 recurred in margin, 1 recurred out of
field. In the arm with CTV, of the 6 patients with local relapse, 4 recurred in-field, 1 recurred in margin, 1 recurred out of
field. The distant metastases rates were 42.6% and 51.4% (p = 0.274) respectively. Grade 3-4 hematological toxicity and
radiation esophagitis had no statistically significant, but grade 3-4 radiation pneumonia was observed in only 7.4% in the
arm without CTV, compared 22.9% in the arm with CTV (p = 0.040). The median survival in the arm without CTV had not
reached, compared with 38 months in the with CTV arm. The l- years, 2- years, 3- years survival rates of the arm without
CTV and the arm with CTV were 81.0%, 66.2%, 61.5% and 88.6%, 61.7%, 56.6% (p = 0.517). The multivariate
analysis indicated that the distant metastases (p = 0.000) and PCI factor (p = 0.004) were significantly related to
overall survival.
Conclusions: Target delineation omitting CTV for limited-disease small cell lung cancer received IMRT was feasible.
The distant metastases and PCI factor were significantly related to overall survival.
Keywords: Radiotherapy, Lung cancer, Limited-disease small cell lung cancer, Clinical target volume, Local relapse,
Intensity-modulated radiotherapy, Radiation pneumoniaBackground
Lung cancer constitutes the major cause of cancer-
related mortality worldwide. Small cell lung cancer
(SCLC) accounts for 15%-25% among lung cancer and
of which 25% - 40% were limited diseases [1]. About
80-90% of patients with limited disease respond to
chemotherapy but relapse generally occurs with median
time of 8 months; local recurrence occurs in 90% of* Correspondence: zgypu@aliyun.com
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reproduction in any medium, provided the orpatients treated with chemotherapy alone. This led to the
use of radiotherapy to local disease in an effort to improve
local control and survival. The most common chemother-
apy regimen is carboplatin and etoposide. This is also used
in concurrent therapy. Radiotherapy should be delivered
concurrently with chemotherapy (randomised trial), and
with the 1st or 2nd cycle of chemotherapy. The early de-
livery of concurrent chemotherapy with chest irradiation
has become the current treatment standard for LSCLC
[2-4]. The lung itself is regarded as a very sensitive organ
to radiation damage. In delivering radiation therapy to the
lung and mediastinum, attention must be devoted to. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dressed the consequences of radiation pneumonia, which
might be a life threatening complication [5,6].
Following ICRU 62, the gross tumor volume (GTV)
is the volume that contains the visible or clinically
detectable tumor, this may be on clinical examination
or on imaging. The clinical target volume (CTV) is a
tissue volume that contains a GTV and/or subclinical
microscopic malignant disease, which has to be elim-
inated. This volume has to be treated adequately in
order to achieve the aim of the therapy: cure or pal-
liation. The internal target volume (ITV) includes a
margin to account for physiological patient move-
ments that are unable to be accounted for during
treatment. This may include movement of the gut,
beating of the heart or respiration. The margin re-
quired is known as the internal margin and may vary
in height, breadth and depth based on the location
within the body. The ITV is a newer concept that at-
tempts to divide treatment inaccuracies into internal
patient factors and external factors. If a method to
reduce the effect of internal movements is used (eg.
respirator gating), then the ITV can be substantially
reduced. The plan target volume (PTV) is a geomet-
rical concept, and it is an expansion from the ITV to
account for external treatment inaccuracies. These
may vary based on the department and the treatment
site. This distance is the external margin. Improving the
external factors which lead to treatment inaccuracies may
reduce the external margin and allow for smaller PTV ex-
pansions. Delineation of GTV, CTV, ITV and PTV is
now the standard for current intensity-modulated
radiotherapy for patients with LSCLC. But RTOG
0617, whose delineation of target volume was accordant
with ICRU 62, failed to escalate the dose from 60 Gy to 74
Gy because more toxicities. The radiation oncologists are
considering where we should go next. Shrinking the treat-
ment volume with dose escalation may be a reasonable
way. Usually the small cell lung cancer is more sensitive to
radiation than non-small cell lung cancer. So the study to
investigate the feasibility of target delineation omitting




Feasibility of omitting clinical target volume for limited-
disease small cell lung cancer treated with chemotherapy
and intensity-modulated radiotherapy.
Patients
89 patients were treated in the Department of Radi-
ation Oncology at Peking University Cancer Hospital
from January 1, 2008 to August 31, 2011. Limiteddisease being defined as tumor confined to one hemi
thorax, including regional lymph nodes, ipsilateral
hilar, bilateral mediastinal and bilateral supraclavicu-
lar nodes without pleural effusion. The entry criteria
were as follows: cytological or histological proven
SCLC; WHO performance status 0-1. Staging proce-
dures included as basic laboratory studies, computed
tomography (CT) of the chest with contrast, CT or
ultrasound imaging of the abdomen, bone emission
computerized tomography (ECT) and brain CT or
magnetic resonance imaging (MRI). Exclusion criteria
were receipt of tumor resection; prior thoracic cancer;
thoracic radiation; a diagnosis of other primary cancer
(other than skin cancer). All patients in this study were
untreated before been recruited.Treatment schedule
Conventional simulation CT scans were acquired with
5-mm slices. The pulmonary extent of lung tumors were
delineated on pulmonary windows (width 1600 HU, level-
600 HU) and the mediastinal lymph nodes were delineated
on mediastinal windows (width 400 HU, level 20 HU).
In the with CTV arm, target volume was delineated ac-
cording to the definition of ICRU62. The GTV was delin-
eated according to CT or PET, a lymph node was
considered to be involved with tumor if it was positive on
biopsy or on PET or was ≥10 mm in the short axis on CT.
A margin of 8 mm to cover microscopic spread of disease
was added to GTV to form the CTV. A 3- to 15-mm mar-
gin was added to create an ITV to cover respiratory move-
ment; respiratory movement for every patient was
measured on conventional simulator, not 4D CT during
free breathing. A 5-mm margin was added to create the
PTV considering setup variations.
In the without CTV arm, the CTV was omitted, the
GTV, ITV and PTV was delineated at the same way
with the control arm.
Both arms were irradiated post chemotherapy tumor
extent if received Induction chemotherapy and omitted
elective nodal irradiation. Dose prescription was 95%
PTV56-63 Gy/28-35 F/5.6-7 weeks.
The IMRT plans were developed by using a com-
mercial treatment-planning system (Varian Medical
Systems). Normal structures delineated included lung
(excluding the GTV from the rest of the lung paren-
chyma), heart, esophagus, and spinal cord with a 5-mm
margin as the planning organ-at-risk margin. Patients
who achieved partly remission (PR) of tumor after the
completion of chemoradiotherapy were offered prophy-
lactic cranial irradiation (PCI), however, some patients
failed to followed doctor’s advices or refused to receive
cranial irradiation , only 46 patients underwent PCI. Dose
prescription was PTV 25 Gy/10F/2 weeks.





No. of eligible patients 54(100) 35(100)
Treatment schedule
Induction chemo + RT 6(11.1) 8(22.9)
Concurrent chemo alone 2(3.7) 2(5.7)
Induction + concurrent t adjuvant chemo 11(20.4) 13(37.1)
Induction + concurrent chemo 26(48.1) 10(28.6)
Concurrent + adjuvant chemo 8(14.8) 2(5.7)
Cai et al. Radiation Oncology 2014, 9:17 Page 3 of 7
http://www.ro-journal.com/content/9/1/17Follow-up
Patients were followed up at regular intervals, usually
every 3-4 months for the first 2 years after treatment,
then every 6 months during 3-5 years. Follow-up exam-
inations included basic laboratory studies, liver and
renal function tests, CT of the chest, CT or MRI of the
brain, and positron emission tomography (PET) when
needed. Relapse in-margin was defined as the region 5mm
inside and outside of PTV. Relapse in-field and out-of-field
were defined as in and out the area of relapse in-margin re-
spectively. The final follow-up time was June 30, 2012.
Statistical analysis
Statistical analysis was performed with SPSS 17.0. Overall
survival, progression free survival and local relapse free
survival were calculated for all patients on an intention-to-
treat basis, using the Kaplan–Meier method and starting
from the first day of the treatment. Patients lost to follow-
up or alive at the time of analysis were censored at the time
of last follow-up.
The differences between the two arms were assessed using
λ2-test or Fisher’s exact tests for the categorical outcome var-
iables. The influence of variables for survival was studied by
Kaplan-Meier analysis and Cox regression analysis.
Results
From January 1, 2008 to August 31, 2011, in the
Department of Radiation Oncology at Peking University
Cancer Hospital, 89 patients were evaluated in the study,
54 cases were irradiated with target volume without CTV,
35 cases with target volume with CTV. Patients character-











Median 56 57 0.548
Range 36-78 38-76
≤65 years 47(87.0) 30(85.7)






>5% 8(14.8) 5(14.3)The cisplatin plus etoposide regimen was the standard
scheme for SCLC [7]. In the study, the arm with CTV
accepted 1.87 ± 1.56 cycle induction chemotherapy, 1.65 ±
0.81 cycle concurrent chemotherapy, 0.59 ± 0.92 cycle
adjuvant chemotherapy; the arm without CTV accepted
2.4 ± 1.63 cycle induction chemotherapy, 1.63 ± 1.09 cycle
synchronous chemotherapy, 0.83 ± 1.07 cycle adjuvant
chemotherapy. Treatment delivery was listed in Table 2.Response and survival
The volumes and dosage of GTV and PTV and short-
term response rate of both arms were listed in Table 3.
Analysis of survival data was made after median
follow-up of 20 months (range 6-53 months). In the whole
89 cases, local relapse occurred in 15 out of 89 patients
(16.6%), distant metastasis 41 out of 89 patients (46.1%), l
years, 2 years, 3 years survival rates were 79%, 63%, 53%,

















Without PCI 25(46.3) 18(51.4)
With PCI 29(53.7) 17(48.6)
Table 3 The volumes and dosage of GTV and PTV and
short-term response rate of both arms
Characteristic Arm without CTV Arm with CTV p-value
Volumes (cm3)
GTV 38.3 ± 5.0 37.3 ± 3.8 0.329
PTV 199.2 ± 19.1 327.4 ± 26.5 0.000
Dosage(Gy)
GTV 67.1 ± 2.0 66.7 ± 2.5 0.386
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lapse rates were 16.7% and 17.1% (p = 0.586), the distant
metastases rates were 42.6% and 51.4% (p = 0.274) re-
spectively, difference between local relapses and distant
metastasis had no statistically significant. The sites of re-
lapse were listed in Table 4.
The median overall survival time in the without CTV
arm hadn’t reached, compared with 38.0 months (95%CI:
28.4-47.6) in the with CTV arm. The l- years, 2- years,
3- years overall survival rates of without CTV arm and
with CTV arm were 81.0%, 66.2%, 61.5% and 88.6%,
61.7%, 56.6% (p = 0.517),the overall survival had no statisti-
cally significant difference between both arms (Figure 1a).Table 4 Site of relapse of LSCLC patients receiving
chemotherapy and IMRT
Characteristic Arm without CTV n (%) Arm with CTV n (%)
No. of eligible patients 54(100) 35(100)
Relapse site




Distant metastasis* 23(42.6) 18(51.4)
Distant alone 17(31.5) 13(37.1)






Adrenal gland 3(5.6) 1(2.9)
Peritoneum LN 2(3.7) 3(8.6)
# p = 0.586 *p = 0.274.The difference in local relapse free survival and distant me-
tastasis free survival between without CTV arm and with
CTV arm had no statistically significant (p = 0.933 and
p = 0.565) (Figure 1b and c).
46 patients were administered prophylactic cranial ir-
radiation (PCI), dose prescription was PTV25 Gy/10F/2
weeks, of which 3 cases had accident of brain metastasis.
Other 43 patients hadn’t received PCI, 15 case had acci-
dent of brain metastasis (p = 0.001). The median survival
in with PCI arm was 52 months, compared with 22
months in the without PCI arm. LSCLC treated with PCI
decreased brain metastases and benefited the survival time.
The difference between with PCI and without PCI had sta-
tistically significant (p = 0.001) (Figure 2).
Univariate analysis and subsequently multivariate ana-
lyses were performed. No pre-treatment factor was sig-
nificantly related to overall survival. The multivariate
analysis indicated that the distant metastases (p = 0.000)
and PCI factor (p = 0.004) were significantly related to
overall survival by Cox regression.Radiation-related toxicity
Radiation-related toxicity was scored according to the
Common Terminology Criteria for Adverse Events
(CTCAE 3.0). In neither arm was a treatment-related
death observed. The treatment-related toxicity was sum-
marized in Table 5.Discussion
IMRT has improved the ability to deliver higher radi-
ation doses to tumors while spare surrounding normal
structures. Many advances have been achieved now-
adays. These include CT-based treatment planning, con-
formal radiation therapy, positron emission tomography
and knowledge of tumor motion during radiation deliv-
ery. So it has become more common in the treatment of
SCLC. A trend in modern thoracic radiotherapy is to-
ward more conformal fields. Emerging clinical data show
that omitting prophylactic lymph node irradiation for
Limited-Stage SCLC did not reduce the local control
rate for patients receiving thoracic radiotherapy, the iso-
lated outside-field local recurrence rates were less than
8% [8,9]. The rate of isolated nodal failure not using
elective nodal irradiation (ENI) was similar to what re-
ported in studies using ENI [10-12]. Hu X [13] prelimin-
ary results indicated that irradiated post chemotherapy
tumor extent and omitted elective nodal irradiation did
not decrease local regional control and the overall survival
difference was not statistically significant. The local recur-
rence rates were 31.6% (12 of 38) and 28.6% (12 of 42), re-
spectively (p =0.81). The isolated nodal failure rates were
2.6% (1 of 38) and 2.4% (1 of 42), respectively (p =1.00). All
the effort was to reduce the irradiation volumes then
Figure 1 Kaplan-Meier analysis of overall survival (a), local relapse free survival (b) and progress free survival (c) for the patients target
delineation without CTV and with CTV in limited small cell lung cancer.
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gional control at the same time.
The RTOG 0617 trial involved 419 patients with stage III
NSCLC, and compared high-dose (74 Gy) with standard-
dose (60 Gy) radiation. All patients also received chemo-
therapy with paclitaxel and carboplatin. From the interim
results, we saw that the higher dose of radiation (74 Gy)
was associated with a higher rate of serious (grade 3)
esophagitis (21% vs. 7%, p = 0.0003) and more treatment-
related deaths (10 vs. 2).Compared high-dose with
standard-dose , the PFS was 26.3% vs. 36.6% (p = 0.0116)
and the OS was 53.9% vs. 66.9% at 18 months, medianFigure 2 Kaplan-Meier analysis of overall survival for the
patients without PCI and with PCI in limited small cell
lung cancer.OS 19.5 vs. 28.7 months (p = 0.0007). The results Were
Surprising. It is possible that the high dose increased radi-
ation to the heart, extended therapy, or caused unreported
toxicity, or it could be a combination of these factors. So
we cannot elevate doses in spite of radiation toxicity.
What is the next step? Can we treat LSCLC with
smaller tumor volume using IMRT? Is CTV necessary?
CTV includes the GTV plus a margin to encompass
subclinical or microscopic malignant disease immedi-
ately adjacent to GTV. In lung cancer, a study [14] dem-
onstrated that GTV-to-CTV expansions of 6 mm for
squamous carcinoma and 8 mm for adenocarcinoma are
required to cover the gross tumor and microscopic dis-
ease. Expansions for SCLC have not been determined,
but a conservative approach would be to use 8 mm be-
cause of the character of its invasive growth.
Obviously, thoracic radiotherapy omitting CTV reduced
the radiation volume, what we concerned most was
whether omitting CTV result in high local relapse rate. In
the study, the local relapse rates were 16.7% in arm withoutTable 5 Toxicities experienced of LSCLC patients







0-2 40 (74.1) 25(71.4)
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ated the impact of PET scan usage on selective nodal ir-
radiation in patients with LSCLC and their results showed
a low isolated nodal failure rate of 3% [15,16]. The major
local relapse was in-field local relapse, the in-field recur-
rences were presented in the place where hadn’t reached
complete response in the initial region. The possible reason
was the existing of radiation-resisted cancer cell which
need higher irradiation doses to enhance local control
[17,18]. Currently ongoing trial compares 45Gy twice-daily
dose with a 2 Gy once-daily to 66-70Gy concomitantly
with EP regimen chemotherapy. We look forward to seeing
whether the higher dose result in the improvement of local
control and long-term survival.
In the study, with the reduction of the thoracic radi-
ation volume in the arm without CTV, grade 3-4 radi-
ation esophagitis occurred in 25.9% while 40.0% in the
arm with CTV (p = 0.123). Grade 3-4 acute radiation
pneumonia was more pronounced in 22.9% of patients
in the arm with CTV, while it was observed in only 7.4%
in the arm without CTV (p = 0.040). Thoracic radiother-
apy omitting CTV had decreased esophageal and lung
toxicity, improve the patients quality of life, which sug-
gests the possibility of dose escalation and allows for
concurrent systemic chemoradiotherapy in a greater
proportion of patients.
To the best of our knowledge, this was the first clinical
study reporting target delineation without CTV in LSCLC.
There were several possible reasons for this philosophy.
First, SCLC is an aggressive type of lung cancer character-
ized by rapid growth and early distant metastasis; in the
study, 16.6% patients suffer local relapse, 46.1% patients
suffer distant metastasis, study indicated that the distant
metastases and PCI factor were significantly related to
overall survival. Patients would have died of distant metas-
tasis before the local failure became clinically apparent. It
was the distant metastasis which eventually leads to death;
by contrast, local relapse was the subordinate factor in the
cause of death. If distant metastases cannot be controlled,
what is the meaning of perfect local disease control? En-
larged radiation field only lead to more damage produced
by radiation. Secondly, micro-metastasis in CTV may have
been small enough to be eliminated by effective chemo-
therapy due to the sensitivity of SCLC to chemotherapy.
Furthermore the tumor cells scattered in CTV were in
oxygen enrichment condition and had better radiation sen-
sitivity [19].In the arm without CTV, the dose of PTV
reach 62Gy, at the region of 8mm expansion of the PTV,
the mean dose reach 32Gy in dosimetric report. Study
[20,21] indicated that incidental dose to the ipsilateral
hilum, paratracheal and mediastinal nodes approach 40-50
Gy when these regions were not intentionally irradiated.
The incidental dose was enough to eliminate the
microscopic spread cancer cells.Conclusion
In conclusion, the preliminary results indicated that
thoracic radiotherapy omitting CTV for limited-disease
small cell lung cancer did not increase loco-regional failure
while significantly fewer patients suffered from grade 3-4
acute radiation pneumonia. So we concluded that target
delineation omitting CTV for limited-disease small cell
lung cancer received IMRT may be feasible. Further inves-
tigation is warranted.
Abbreviations
GTV: Gross tumor volume; CTV: Clinical target volume; ITV: Internal target
volume; PTV: Plan target volume; SCLC: Small cell lung cancer;
LSCLC: Limited-disease small cell lung cancer; CT: Computed tomography;
ECT: Emission computerized tomography; MRI: Magnetic resonance imaging;
PET: Positron emission tomography; PCI: Prophylactic cranial irradiation;
ENI: Elective nodal irradiation; CR: Complete remission; PR: Partial response;
SD: Stable disease; PD: Progressive disease.
Competing interests
The authors have declared that no competing interests exist.
Authors’ contributions
SC selected the data and performed the analysis, drafted and wrote the
manuscript. AS and RY were responsible for patient treatment and care. GZ
contributed substantially to conception and design, reviewed and revised
the manuscript. All authors read and approved the final manuscript.
Author details
1Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fujian
Medical University Teaching Hospital, 420# Fuma Road, Fuzhou 350014,
People’s Republic of China. 2Key Laboratory of Carcinogenesis and Translational
Research (Ministry of Education), Department of Radiation Oncology, Peking
University Cancer Hospital & Institute, 52# Fucheng Road, Beijing 100142,
People’s Republic of China.
Received: 8 July 2013 Accepted: 3 January 2014
Published: 10 January 2014
References
1. Youlden DR, Cramb SM, Baade PD: The International Epidemiology of
Lung Cancer: geographical distribution and secular trends. J Thorac Oncol
2008, 3(8):819–831.
2. Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, Gilligan D,
Murray PA, de Elvira MC R, O'Donnell KM, Gower NH, Harper PG, Hackshaw AK:
Early compared with late radiotherapy in combined modality treatment for
limited disease small-cell lung cancer: A London Lung Cancer Group
multicenter randomized clinical trial and meta-analysis. J Clin oncol 2006,
24:3823–3830.
3. Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF:
Early versus late chest radiotherapy for limited stage small cell lung
cancer. Cochrane Database Syst Rev 2005, 25(1), CD004700.
4. De Ruysscher D, Pijls-Johannesma MCG, Bentzen SM, Minken: A Time
between the first day of chemotherapy and the last day of chest
radiation is the most important predictor of survival in limited disease small
cell lung cancer. J Clin Oncol 2006, 24:1057–1063.
5. Yorke ED, Jackson A, Rosenzweig KE, Merrick SA, Gabrys D, Venkatraman ES,
Burman CM, Leibel SA, Ling CC: Dose-volume factors contributing to the
incidence of radiation pneumonitis in non-small-cell lung cancer patients
treated with three-dimensional conformal radiation therapy. Int J Radiat
Oncol Biol Phys 2002, 54(2):329–339.
6. Kong FM, Hayman JA, Griffith KA, Kalemkerian GP, Arenberg D, Lyons S,
Turrisi A, Lichter A, Fraass B, Eisbruch A, Lawrence TS, Ten Haken RK: Final
toxicity results of a radiation-dose escalation study in patients with
non–small-cell lung cancer (NSCLC): predictors for radiation pneumonitis
and fibrosis. Int J Radiat Oncol Biol Phys 2006, 65(4):1075–1086.
7. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, Boye N,
Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S: Cisplatin
and etoposide regimen is superior to cyclophosphamide, epirubicin, and
Cai et al. Radiation Oncology 2014, 9:17 Page 7 of 7
http://www.ro-journal.com/content/9/1/17vincristine regimen in small-cell lung cancer: results from a randomized
phase III trial with 5 years follow-up. J Clin Oncol 2002, 20(24):4665–4672.
8. Xia B, Chen GY, Cai XW, Zhao JD, Yang HJ, Fan M, Zhao KL, Fu XL: Is
involved-field radiotherapy based on CT safe for patients with limited-
stage small-cell lung cancer? Radiother Oncol 2012, 102:258–262.
9. Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LW, Brade A, Cho J, Leighl NB,
Shepherd FA, Hope AJ: Locoregional failures following thoracic irradiation
in patients with limited-stage small-cell lung carcinoma. Radiother Oncol
2012, 102:263–267.
10. Tada T, Minakuchi K, Koda M, Masuda N, Matsui K, Kawase I, Nakajima T,
Nishioka M, Fukuoka M, Kozuka T: Limited-stage small cell lung cancer:
local failure after chemotherapy and radiation therapy. Radiology 1998,
208:511–515.
11. Wierzchowski M, Sprawka A, Kepka L: Isolated nodal failure after
chemoradiotherapy in limited disease small cell lung cancer (LD-SCLC).
Rep Pract Oncol Radiother 2009, 14:58–63.
12. Chen M, Bao Y, Ma HL, Hu X, Wang J, Wang Y, Peng F, Zhou QC, Xie CH:
Involved-field radiotherapy versus elective nodal irradiation in combination
with concurrent chemotherapy for locally advanced non-small cell lung
cancer: a prospective randomized study. Biomed Res Int 2013, 2013:371819.
13. Hu X, Bao Y, Zhang L, Guo Y, Chen YY, Li KX, Wang WH, Liu Y, He H, Chen M:
Omitting elective nodal irradiation and irradiating postinduction versus
preinduction chemotherapy tumor extent for limited-stage small cell lung
cancer: interim analysis of a prospective randomized non inferiority trial.
Cancer 2012, 118(1):278–287.
14. Giraud P, Antoine M, Larrouy A, Milleron B, Callard P, De Rycke Y, Carette MF,
Rosenwald JC, Cosset JM, Housset M, Touboul E: Evaluation of microscopic
tumor extension in non-small-cell lung cancer for three-dimensional
conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000,
48:1015–1024.
15. van Loon J, Offermann C, Bosmans G, Wanders R, Dekker A, Borger J, Oellers M,
Dingemans AM, van Baardwijk A, Teule J, Snoep G, Hochstenbag M, Houben R,
Lambin P, De Ruysscher D: 18FDG-PET based radiation planning of
mediastinal lymph nodes in limited disease small cell lung cancer changes
radiotherapy fields: a planning study. Radiother Oncol 2008, 87:49–54.
16. van Loon J, De Ruysscher D, Wanders R, Boersma L, Simons J, Oellers M,
Dingemans AM, Hochstenbag M, Bootsma G, Geraedts W, Pitz C, Teule J,
Rhami A, Thimister W, Snoep G, Dehing-Oberije C, Lambin P: Selective nodal
irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung
cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010, 77:329–336.
17. Komaki R, Swann RS, Ettinger DS, Glisson BS, Sandler AB, Movsas B, Suh J,
Byhardt RW: Phase I study of thoracic radiation dose escalation with
concurrent chemotherapy for patients with limited small-cell lung
cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.
Int J Radiat Oncol Biol Phys 2005, 62(2):342–350.
18. Bogart JA, Herndon JE 2nd, Lyss AP, Watson D, Miller AA, Lee ME, Turrisi AT,
Green MR: 70 Gy thoracic radiotherapy is feasible concurrent with
chemotherapy for limited-stage small-cell lung cancer: Analysis of
Cancer and Leukemia Arm B study 39808. Int J Radiat Oncol Biol Phys
2004, 59(2):460–468.
19. Littbrand B, Revesz L: The effect of oxygen on cellular survival and
recovery after radiation. Br J Radiol 1969, 42:914–924.
20. Zhao L, Chen M, Ten Haken R, et al: Three-dimensionalconformal radiation
may deliver considerable dose of incidental nodal irradiation in patients
with early stage node-negative non-small cell lung cancer when the
tumor is large and centrally located. Radiother Oncol. 2007, 82:153–159.
21. Chen M, Hayman JA, Ten Haken RK, Tatro D, Fernando S, Kong FM: Long-term
results of high-dose conformalradiotherapy for patients with medically
inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional
failure due to incidental nodal irradiation? Int J Radiat Oncol Biol Phys 2006,
64:120–126.
doi:10.1186/1748-717X-9-17
Cite this article as: Cai et al.: Feasibility of omitting clinical target
volume for limited-disease small cell lung cancer treated with
chemotherapy and intensity-modulated radiotherapy. Radiation Oncology
2014 9:17.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
